Erratum to: Impaired T cell function in malignant pleural effusion is caused by TGF-β derived predominantly from macrophages: Impaired T Cell Function in Malignant Pleural Effusion (International Journal of Cancer, (2016), 139, 10, (2261-2269), 10.1002/ijc.30289);Impaired T cell function in malignant pleural effusion is caused by TGF-β derived predominantly from macrophages

International Journal of Cancer

Volumn 139, Issue 10, 2016, Pages 2261-2269

  Li, Lifeng ^a   Yang, Li ^a   Wang, Liping ^a   Wang, Fei ^a,b   Zhang, Zhen ^a   Li, Jieyao ^a   Yue, Dongli ^a   Chen, Xinfeng ^a   Ping, Yu ^a,b   Huang, Lan ^a   Zhang, Bin ^c   Zhang, Yi ^a,b  

^a THE FIRST AFFILIATED HOSPITAL OF ZHENGZHOU UNIVERSITY   (China)

^b ZHENGZHOU UNIVERSITY   (China)

^c NORTHWESTERN UNIVERSITY   (United States)

Author keywords

CD4+ T cells; CD8+ T cells; impaired T cell function; malignant pleural effusion (MPE); TGF ; tumor associated macrophages (TAMs)

Indexed keywords

CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; GAMMA INTERFERON; GRANZYME B; INTERLEUKIN 10; MESSENGER RNA; PROGRAMMED DEATH 1 RECEPTOR; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR;

ADULT; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL MEDIATED CYTOTOXICITY; CLINICAL ARTICLE; COCULTURE; CONTROLLED STUDY; CYTOKINE PRODUCTION; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; LUNG CANCER; MACROPHAGE; MALIGNANT PLEURA EFFUSION; MONONUCLEAR CELL; MYELOID DERIVED SUPPRESSOR CELL; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; SUPPRESSOR CELL; T LYMPHOCYTE; TUMOR ASSOCIATED LEUKOCYTE;

EID: 84986601867     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.34205     Document Type: Erratum

References (47)

1. Simpson G, Judge DJ. Management of malignant pleural effusion. Respirology 2015;20:169
2. Beck C, Schreiber H, Rowley D. Role of TGF-beta in immune-evasion of cancer. Microsc Res Tech 2001;52:387–95.
3. Kawamura K, Bahar R, Natsume W, et al. Secretion of interleukin-10 from murine colon carcinoma cells suppresses systemic antitumor immunity and impairs protective immunity induced against the tumors. Cancer Gene Ther 2002;9:109–15.
4. Filipazzi P, Huber V, Rivoltini L. Phenotype, function and clinical implications of myeloid-derived suppressor cells in cancer patients. Cancer Immunol Immunother 2012;61:255–63.
5. Facciabene A, Motz GT, Coukos G. T-regulatory cells: key players in tumor immune escape and angiogenesis. Cancer Res 2012;72:2162–71.
6. Ruffell B, Affara NI, Coussens LM. Differential macrophage programming in the tumor microenvironment. Trends Immunol 2012;33:119–26.
7. Coffelt SB, Hughes R, Lewis CE. Tumor-associated macrophages: effectors of angiogenesis and tumor progression. Biochim Biophys Acta 2009;1796:11–8.
8. Rogers TL, Holen I. Tumour macrophages as potential targets of bisphosphonates. J Transl Med 2011;9:177.
9. Kaczmarek M, Nowicka A, Kozlowska M, et al. Evaluation of the phenotype pattern of macrophages isolated from malignant and non-malignant pleural effusions. Tumour Biol 2011;32:1123–32.
10. Bingle L, Brown NJ, Lewis CE. The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies. J Pathol 2002;196:254–65.
11. Mantovani A, Allavena P, Sica A. Tumour-associated macrophages as a prototypic type II polarised phagocyte population: role in tumour progression. Eur J Cancer 2004;40:1660–7.
12. Zhuo C, Xu Y, Ying M, et al. FOXP3 + Tregs: heterogeneous phenotypes and conflicting impacts on survival outcomes in patients with colorectal cancer. Immunol Res 2015;61:338–47.
13. Qu P, Wang LZ, Lin PC. Expansion and functions of myeloid-derived suppressor cells in the tumor microenvironment. Cancer Lett 2015;pii: S0304–3835(15)00653-9.
14. Syed V. TGF-β signaling in cancer. J Cell Biochem 2016;117:1279–87.
15. Ye ZJ, Xu LL, Zhou Q, et al. Recruitment of IL-27-producing CD4(+) T cells and effect of IL-27 on pleural mesothelial cells in tuberculous pleurisy. Lung 2015;193:539–48.
16. + T cells in human tuberculous pleural effusion. Tuberculosis (Edinb) 2014;94:579–88.
17. Shi B, Du X, Wang Q, et al. Increased PD-1 on CD4(+)CD28(−) T cell and soluble PD-1 ligand-1 in patients with T2DM: association with atherosclerotic macrovascular diseases. Metabolism 2013;62:778–85.
18. Fritz JM, Tennis MA, Orlicky DJ, et al. Depletion of tumor-associated macrophages slows the growth of chemically induced mouse lung adenocarcinomas. Front Immunol 2014;5:587.
19. Staudt ND, Jo M, Hu J, et al. Myeloid cell receptor LRP1/CD91 regulates monocyte recruitment and angiogenesis in tumors. Cancer Res 2013;73:3902–12.
20. Guedez L, Jensen-Taubman S, Bourboulia D, et al. TIMP-2 targets tumor-associated myeloid suppressor cells with effects in cancer immune dysfunction and angiogenesis. J Immunother 2012;35:502–12.
21. Katoh H, Wang D, Daikoku T, et al. CXCR2-expressing myeloid-derived suppressor cells are essential to promote colitis-associated tumorigenesis. Cancer Cell 2013;24:631–44.
22. Li WM, Liu HR. CCL20-CCR6 cytokine network facilitate Treg activity in advanced grades and metastatic variants of hepatocellular carcinoma. Scand J Immunol 2016;83:33–7.
23. Lv M, Xu Y, Tang R, et al. miR141-CXCL1-CXCR2 signaling-induced Treg recruitment regulates metastases and survival of non-small cell lung cancer. Mol Cancer Ther 2014;13:3152–62.
24. Froudarakis ME. Pleural effusion in lung cancer: more questions than answers. Respiration 2012;83:367–76.
25. + macrophages, a potential immune biomarker for malignant pleural effusion. Cancer Immunol Immunother 2015;64:965–76.
26. + tumor-associated macrophage is a prognostic biomarker and is associated with therapeutic effect on malignant pleural effusion of lung cancer patients. Oncotarget 2015;6:10592–603.
27. Sica A, Schioppa T, Mantovani A, et al. Tumour-associated macrophages are a distinct M2 polarised population promoting tumour progression: potential targets of anti-cancer therapy. Eur J Cancer 2006;42:717–27.
28. Yingling JM, Blanchard KL, Sawyer JS. Development of TGF-beta signalling inhibitors for cancer therapy. Nat Rev Drug Discov 2004;3:1011–22.
29. Ivanovic V, Melman A, Davis-Joseph B, et al. Elevated plasma levels of TGF-beta 1 in patients with invasive prostate cancer. Nat Med 1995;1:282–4.
30. Narai S, Watanabe M, Hasegawa H, et al. Significance of transforming growth factor beta1 as a new tumor marker for colorectal cancer. Int J Cancer 2002;97:508–11.
31. Kong F, Jirtle RL, Huang DH, et al. Plasma transforming growth factor-beta1 level before radiotherapy correlates with long term outcome of patients with lung carcinoma. Cancer 1999;86:1712–9.
32. Ivanovic V, Demajo M, Krtolica K, et al. Elevated plasma TGF-beta1 levels correlate with decreased survival of metastatic breast cancer patients. Clin Chim Acta 2006;371:191–3.
33. Schneider T, Sailer M, Ansorge S, et al. Increased concentrations of transforming growth factor beta1 and beta2 in the plasma of patients with glioblastoma. J Neurooncol 2006;79:61–5.
34. Wahl SM, Swisher J, McCartney-Francis N, et al. TGF-beta: the perpetrator of immune suppression by regulatory T cells and suicidal T cells. J Leukoc Biol 2004;76:15–24.
35. Ahmadzadeh M, Rosenberg SA. TGF-beta 1 attenuates the acquisition and expression of effector function by tumor antigen-specific human memory CD8 T cells. J Immunol 2005;174:5215–23.
36. Alard P, Clark SL, Kosiewicz MM. Mechanisms of tolerance induced by TGF beta-treated APC: CD4 regulatory T cells prevent the induction of the immune response possibly through a mechanism involving TGF beta. Eur J Immunol 2004;34:1021–30.
37. Lee YJ, Han Y, Lu HT, et al. TGF-beta suppresses IFN-gamma induction of class II MHC gene expression by inhibiting class II transactivator messenger RNA expression. J Immunol 1997;158:2065–75.
38. + regulatory T cells by combinations of IL-2, TGF-beta, retinoic acid, rapamycin and butyrate. PLoS One 2016;11:e0148474
39. Vadrevu SK, Chintala NK, Sharma SK, et al. Complement c5a receptor facilitates cancer metastasis by altering T-cell responses in the metastatic niche. Cancer Res 2014;74:3454–65.
40. Qi J, Li D, Feng J, et al. Native soluble carcinoembryonic antigen is not involved in the impaired activity of CD56 natural killer cells in malignant pleural effusion. Respiration 2013;86:216–23.
41. Biswas S, Criswell TL, Wang SE, et al. Inhibition of transforming growth factor-beta signaling in human cancer: targeting a tumor suppressor network as a therapeutic strategy. Clin Cancer Res 2006;12:4142–6.
42. Nemunaitis J, Dillman RO, Schwarzenberger PO, et al. Phase II study of belagenpumatucel-L, a transforming growth factor beta-2 antisense gene-modified allogeneic tumor cell vaccine in non-small-cell lung cancer. J Clin Oncol 2006;24:4721–30.
43. Herbertz S, Sawyer JS, Stauber AJ, et al. Clinical development of galunisertib (LY2157299 monohydrate), a small molecule inhibitor of transforming growth factor-beta signaling pathway. Drug Des Dev Ther 2015;9:4479–99.
44. Massagué J, Blain SW, Lo RS. TGFbeta signaling in growth control, cancer, and heritable disorders. Cell 2000;103:295–309.
45. Fujiwara Y, Nokihara H, Yamada Y, et al. Phase 1 study of galunisertib, a TGF-beta receptor I kinase inhibitor, in Japanese patients with advanced solid tumors. Cancer Chemother Pharmacol 2015;76:1143–52.
46. Serova M, Tijeras-Raballand A, Dos Santos C, et al. Effects of TGF-beta signalling inhibition with galunisertib (LY2157299) in hepatocellular carcinoma models and in ex vivo whole tumor tissue samples from patients. Oncotarget 2015;6:21614–27.
47. Heeren AM, Punt S, Bleeker MC, et al. Prognostic effect of different PD-L1 expression patterns in squamous cell carcinoma and adenocarcinoma of the cervix. Modern Pathol 2016. doi: 10.1038/modpathol.2016.64. [Epub ahead of print]